Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pearl Therapeutics IncfiledCriticalPearl Therapeutics Inc
Priority to DO2013000262ApriorityCriticalpatent/DOP2013000262A/en
Publication of DOP2013000262ApublicationCriticalpatent/DOP2013000262A/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Se proporcionan composiciones, métodos y sistemas para suministro pulmonar o nasal de dos o más agentes activos a través de un inhalador de dosis medida. En una modalidad, las composiciones incluyen un medio de suspension, particulas del agente activo, y particulas en suspension, en las que las particulas del agente activo y las particulas en suspension forman una co-suspension dentro del medio suspension.Compositions, methods and systems for pulmonary or nasal delivery of two or more active agents are provided through a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspended particles, in which the active agent particles and suspended particles form a co-suspension within the suspension medium.
DO2013000262A2013-11-132013-11-13
COMPOSITIONS, METHODS AND SYSTEMS FOR THE RESPIRATORY SUPPLY OF TWO OR MORE ACTIVE AGENTS
DOP2013000262A
(en)
Combination pharmaceutical product in the form of dry powder for administration by means of an inhaler comprising a umeclidinium salt of a defined group and 100 mcg / dose of fluticasone furoate, without other additional assets; use for the treatment of inflammatory or respiratory diseases.
Pharmaceutical composition for inhalation comprising aclidinium, with lactose, which provides a dose of 322 ug of free base and approx. 140 ug of aclidinium bromide; a method to treat a respiratory condition selected from asthma and epoc; use of the composition; and a calibrated dry powder inhaler device comprising it